But Byetta has been almost too successful.
The bad news is that Lilly, which distributes Byetta along with Amylin, doesn’t want new patients to start on Byetta right now. They can’t make the pens that Byetta comes in fast enough. Lilly has “asked physicians to temporarily suspend the start of new patients on Byetta until supply and inventory levels are restored.”
Consequently, I almost feel that I am being mean by talking up something that you might not be able to get right now. But my recommendation is to be patient. It’s worth it.
< Previous 1 | Page 2 >
- Font size
- Email This
- Bookmark
- Thank you for your input
- Save
- RSS
- Report Abuse
